Research and Markets: PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130306:nBw065678a DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv) has announced the addition of GlobalData's new report "PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022" to their offering. GlobalData has released its new Country report, PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. Newer STRs are expected to be released and will replace Atripla as the market leader during the forecast period. As a whole, the market share of the STRs will be affected by key patent expiries, such as those of BMS' Sustiva, which is a key component of Atripla. Combined with healthcare budget restrictions imposed by the general financial situation in Europe, this might lead to a drastic drop in Atripla sales and increase the barrier to entry for novel STRs. Scope - Overview of Germany including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Germany from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting Germany HIV market. For more information visit http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv Source: GlobalData Research and Markets Laura Wood, Senior Manager. email@example.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals Copyright Business Wire 2013